Physician profile
Tapas Nuwal
NPI 1033799788
$1,067.21
in general payments reported to CMS, 2019-2025
24 companies · $787 in 2025
The $787 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $280 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $149.78 | 2025 | Repatha, Otezla |
| Novo Nordisk INC | $105.87 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $100.06 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $70.05 | 2025 | Trelegy Ellipta, Shingrix |
| Inspire Medical Systems, INC. | $67.43 | 2024-2025 | Inspire |
| Abbvie INC. | $52.07 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.03 | 2024-2025 | Jardiance |
| Hologic Sales and Service, LLC | $46.14 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Dexcom, INC. | $41.21 | 2024-2025 | Dexcom G6 Transmitter |
| Kestra Medical Technology Services, INC. | $35.57 | 2024 | Assure Wcd |
| Baxter Healthcare | $33.26 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Sumitomo Pharma America, INC. | $32.61 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $29.81 | 2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals Lp | $28.26 | 2025 | Breztri, Farxiga |
| Abiomed | $26.63 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.30 | 2025 | |
| Axsome Therapeutics, INC. | $24.65 | 2025 | Symbravo |
| Abbott Laboratories | $24.11 | 2025 | Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $23.34 | 2025 | |
| Terumo Medical Corporation | $22.63 | 2024 | R2p Misago, Metacross Otw, Glidesheath Slender |
| Astellas Pharma US INC | $21.98 | 2025 | Veozah |
| Lilly USA, LLC | $20.87 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $19.63 | 2024 | |
| Esperion Therapeutics, INC. | $13.92 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tapas Nuwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.